Leadership & Pay ·
Brainstorm Cell Therapeutics appointed Peter Pitts as Executive Chairman and Chief Strategic Regulatory Officer…
BCLIBrainstorm Cell Therapeutics Inc.
Brainstorm Cell Therapeutics appointed Peter Pitts as Executive Chairman and Chief Strategic Regulatory Officer, granting him a stock option for 900,000 shares with no base salary or bonus. Concurrently, Jacob Frenkel resigned as Chairman to become Senior Advisor, receiving accelerated vesting on existing equity and 100,000 restricted stock units under a consulting agreement. Additionally, Chief Medical Officer Ibrahim Dagher resigned effective July 26, 2026, transitioning to a one-year consulting role with specific equity acceleration provisions. These leadership changes position Pitts to oversee the upcoming Phase 3b trial for NurOwn®, an autologous cellular therapy candidate for amyotrophic lateral sclerosis (ALS) under an FDA Special Protocol Assessment. The company operates in the biotechnology sector, developing stem cell therapies for neurodegenerative diseases.